These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 10052898

  • 21. Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicans.
    Calabrese EC, Castellano S, Santoriello M, Sgherri C, Quartacci MF, Calucci L, Warrilow AG, Lamb DC, Kelly SL, Milite C, Granata I, Sbardella G, Stefancich G, Maresca B, Porta A.
    J Antimicrob Chemother; 2013 May; 68(5):1111-9. PubMed ID: 23292344
    [Abstract] [Full Text] [Related]

  • 22. RTA2, a novel gene involved in azole resistance in Candida albicans.
    Jia XM, Ma ZP, Jia Y, Gao PH, Zhang JD, Wang Y, Xu YG, Wang L, Cao YY, Cao YB, Zhang LX, Jiang YY.
    Biochem Biophys Res Commun; 2008 Sep 05; 373(4):631-6. PubMed ID: 18601908
    [Abstract] [Full Text] [Related]

  • 23. Accumulation of 3-ketosteroids induced by itraconazole in azole-resistant clinical Candida albicans isolates.
    Marichal P, Gorrens J, Laurijssens L, Vermuyten K, Van Hove C, Le Jeune L, Verhasselt P, Sanglard D, Borgers M, Ramaekers FC, Odds F, Vanden Bossche H.
    Antimicrob Agents Chemother; 1999 Nov 05; 43(11):2663-70. PubMed ID: 10543744
    [Abstract] [Full Text] [Related]

  • 24. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.
    Sanglard D, Ischer F, Monod M, Bille J.
    Antimicrob Agents Chemother; 1996 Oct 05; 40(10):2300-5. PubMed ID: 8891134
    [Abstract] [Full Text] [Related]

  • 25. FLO8 deletion leads to azole resistance by upregulating CDR1 and CDR2 in Candida albicans.
    Li WJ, Liu JY, Shi C, Zhao Y, Meng LN, Wu F, Xiang MJ.
    Res Microbiol; 2019 Oct 05; 170(6-7):272-279. PubMed ID: 31449848
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
    Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T, Kohno S.
    Antimicrob Agents Chemother; 2000 Jun 05; 44(6):1728-30. PubMed ID: 10817741
    [Abstract] [Full Text] [Related]

  • 27. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
    Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G.
    Antimicrob Agents Chemother; 2005 Feb 05; 49(2):668-79. PubMed ID: 15673750
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Regulation of azole drug susceptibility by Candida albicans protein kinase CK2.
    Bruno VM, Mitchell AP.
    Mol Microbiol; 2005 Apr 05; 56(2):559-73. PubMed ID: 15813744
    [Abstract] [Full Text] [Related]

  • 30. Synergistic activity of magnolol with azoles and its possible antifungal mechanism against Candida albicans.
    Sun LM, Liao K, Liang S, Yu PH, Wang DY.
    J Appl Microbiol; 2015 Apr 05; 118(4):826-38. PubMed ID: 25641229
    [Abstract] [Full Text] [Related]

  • 31. Evolution of drug resistance in experimental populations of Candida albicans.
    Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, Kohn LM.
    J Bacteriol; 2000 Mar 05; 182(6):1515-22. PubMed ID: 10692355
    [Abstract] [Full Text] [Related]

  • 32. In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.
    Mahmoud DE, Faraag AHI, Abu El-Wafa WM.
    World J Microbiol Biotechnol; 2021 Oct 11; 37(11):191. PubMed ID: 34632522
    [Abstract] [Full Text] [Related]

  • 33. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies.
    Vermitsky JP, Earhart KD, Smith WL, Homayouni R, Edlind TD, Rogers PD.
    Mol Microbiol; 2006 Aug 11; 61(3):704-22. PubMed ID: 16803598
    [Abstract] [Full Text] [Related]

  • 34. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
    Johnson EM, Warnock DW, Luker J, Porter SR, Scully C.
    J Antimicrob Chemother; 1995 Jan 11; 35(1):103-14. PubMed ID: 7768758
    [Abstract] [Full Text] [Related]

  • 35. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.
    Bachmann SP, Patterson TF, López-Ribot JL.
    J Clin Microbiol; 2002 Jun 11; 40(6):2228-30. PubMed ID: 12037093
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.